Searchable abstracts of presentations at key conferences in endocrinology

ea0034p273 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Familial adult hyperinsulinism due to genetic glucokinase activation: implications for therapeutic use of glucokinase activators

Challis B G , Harris J , Sleigh A , Orme S M , Seevaratnam N , Dhatariya K , Simpson H L , Semple R K

Glucokinase (GCK) serves as the blood glucose ‘sensor’ in pancreatic β-cells, being critically involved in transducing elevated blood glucose into increased insulin secretion. Inactivating GCK mutations cause a subtype of maturity onset diabetes of the young (MODY), whereas activating mutations are a rare cause of hyperinsulinaemic hypoglycaemia, usually presenting in infancy.We now describe the case of a 60-year-old woman who first presen...

ea0021p402 | Thyroid | SFEBES2009

Clinical management and outcomes of anti-TSH receptor antibody positive pregnancies

Stears A J , Stewart R , Halsall D J , Ogilvy-Stuart A L , Patient C J , Simpson H L , Swamy A , Chatterjee V K

Introduction: Anti-TSH-receptor binding antibodies can cross the placenta and can stimulate or inhibit the fetal thyroid, causing fetal and neonatal thyroid dysfunction. We test for these antibodies in all pregnant women with a history of thyroid disease using a TSH binding inhibitor immunoglobulin (TBII) assay. Our aims were to audit our management of TBII positive pregnancies and to review pregnancy outcomes.Methods: Serum TBII concentration was measur...

ea0031p168 | Neoplasia, cancer and late effects | SFEBES2013

Review of patients with adrenocortical carcinoma at a tertiary referral centre

Deshpande S , Parker V , Ahmed U , Moore D , Jamieson N V , Gurnell M G , Chatterjee V K , Basu B , Corrie P , Simpson H L

Introduction: Adrenocortical carcinoma (ACC) is a rare but devastating malignancy. We performed a review to determine outcome in our patient cohort.Of 20 patients 14 were females, six males. Median overall survival was 27.5 months (range 1–168), nine being deceased. Mean age at presentation 52.3 years (range 18–71). The majority of cancers were large; 5% ≤5 cm, 40% 5–10 cm, 55 >10 cm. 25% had stage IV disease, 10% stage III, 55% ...